Gates backs cervical cancer vaccines for poor

	Tweet

Microsoft Corp founder Bill Gates is putting his financial muscle behind a campaign to get life-saving Cervical cancer vaccines to women in poor countries.

Two rival vaccines targeting the Human papilloma virus (HPV), which causes the disease, are expected to be launched in the next year or two by Merck & Co Inc and GlaxoSmithKline Plc.

But it is unclear how the novel shots will be funded in the developing world, where most deaths from Cervical cancer occur.

In a bid to speed their development and introduction, the World Health Organization (WHO) said it had been granted $7 million by the Bill & Melinda Gates Foundation.

The Gates charity has donated a further $5.9 million to the International Agency for Research on Cancer, Harvard University and the Program for Appropriate Technology in Health.

The money will be used to support various preparatory projects, rather than full-scale vaccination programs.

In the case of the WHO, the cash will be used to develop standards and guidelines for future vaccine schemes. The other groups will work on developing private sector partnerships and studying the epidemiology of HPV and Cervical cancer.

Merck’s product Gardasil is expected to be first to market but GSK’s Cervarix is not far behind, and industry analysts expect both vaccines to become multi billion-dollar sellers.

While both target HPV, a sexually transmitted infection, they vary in the number of strains they attack and the way the vaccine is manufactured.

Cervical cancer kills a quarter of a million women each year, most of them in the developing world.

Jean Stephenne, president of GlaxoSmithKline Biologicals, the vaccines unit of GSK, said on Tuesday he applauded the Gates Foundation’s involvement.

“The work which will be done by the WHO and other recipients of these grants will help in overcoming some of these challenges and accomplishing the goal of getting this vaccine to all women no matter where they live,” he said.

Developing countries are a potentially important market for vaccine manufacturers, which are expected to offer preferential prices for the poor if they can secure large orders and financial backing from governments or charities.

GSK is working with MedImmune on its vaccine while Merck is partnering Gardasil in Europe with Sanofi-Aventis. 

RELATED STORIES:
Study determines costs of breast and cervical cancer detection among low-income women   Stress May Increase a Woman’s Risk of Developing Cervical Cancer   Post-treatment PET Scans Can Reassure Cervical Cancer Patients   Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia   Study indicates vaccine prevents cervical cancer   HPV Vaccine Reduces Abnormal Pap Test Results   15 Common Myths About Cervical Cancer   A Cervical Cancer Screening Month Resolution   Vaccine no replacement for Pap test   Obese women in Canada are less likely to be screened for cervical cancer   HPV tests better for cervical screening - experts   UK mothers back cervical cancer vaccine for kids   CDC recommends human papillomavirus virus vaccination   HIV drug stops cervical cancer in laboratory test   US FDA approves Hycamtin for cervical cancer   New cervical cancer vaccine offers women 100% protection   Merck says US CDC endorses cervical cancer vaccine   Girls should get cervical cancer vaccine, panel says   Phone counseling improves quality of life, immune systems of cervical cancer survivors   Cervical cancer survivors prone to other cancers   Merck cervical cancer shot gives 5-year protection   Cervical cancer screening: Too many are left unprotected

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]